The global intradermal injection market size is expected to surpass an impressive valuation of USD 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

These events are associated with innate training and can have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many ...

When purifying proteins and other actives in production or research environments the aim is to achieve the purest possible ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

In the world of automotive care, the rule “more is better” doesn’t always apply. This is true not only for mileage but also for key operating fluids—especia ...

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.

US FDA designates Celltrion’s Yuflyma as an interchangeable biosimilar to Humira: Incheon, South Korea Wednesday, April 16, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that ...

VIMKUNYA was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 6,7.